NASDAQ
10.09.25 | 21:59
2,635 US-Dollar
-1,68 % -0,045
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | C4 Therapeutics, Inc.: C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | 205 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 04.09. | C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential | 2 | Investing.com | ||
| 03.09. | C4T to host webcast on cemsidomide multiple myeloma trial data | 2 | Investing.com | ||
| 03.09. | C4 Therapeutics, Inc.: C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting | 6 | GlobeNewswire (USA) | ||
| 07.08. | C4 Therapeutics GAAP EPS of -$0.37 | 14 | Seeking Alpha | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.08. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 18.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide | 7 | FierceBiotech | ||
| 07.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.05. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 410 | GlobeNewswire (Europe) | Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100... ► Artikel lesen | |
| 14.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.02. | C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 413 | GlobeNewswire (Europe) | Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial... ► Artikel lesen | |
| 14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology | 253 | GlobeNewswire (Europe) | Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's... ► Artikel lesen | |
| 08.12.24 | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 298 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
| 28.10.24 | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 223 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 15.10.24 | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. | 290 | GlobeNewswire (Europe) | Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific... ► Artikel lesen | |
| 30.09.24 | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 119 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,320 | +2,65 % | Inovio: Fortschritte bei DNA-Medizin und Zulassungsantrag für INO-3107 in Aussicht | ||
| OCUGEN | 0,876 | -1,00 % | Ocugen, Inc. - 8-K, Current Report | ||
| CARDIFF ONCOLOGY | 1,778 | +1,72 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 21,200 | -0,93 % | Celldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) | Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,130 | +1,30 % | Strategiewechsel bei Coherus: Voller Fokus auf Immunonkologie | ||
| NEOVACS | 0,511 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,000 | +0,50 % | Forecasting The Future: 5 Analyst Projections For Arcturus Therapeutics | ||
| ULTRAGENYX | 26,600 | -0,75 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) | At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance Phase... ► Artikel lesen | |
| GYRE THERAPEUTICS | 6,500 | -2,26 % | GYRE THERAPEUTICS, INC. - 8-K, Current Report | ||
| GOSSAMER BIO | 2,590 | -2,41 % | Gossamer Bio higher as UBS upgrades on upcoming data catalyst | ||
| SAGIMET BIOSCIENCES | 5,850 | -4,10 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit | ||
| BIOMEA FUSION | 1,840 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,290 | 0,00 % | Janux is a new Buy at Truist ahead of catalyst rich H2 | ||
| 4D MOLECULAR THERAPEUTICS | 6,945 | 0,00 % | Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" | ||
| TENAYA THERAPEUTICS | 1,300 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,635 Euro und damit -1,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.